Is Homosalate safe in cosmetics?
Homosalate has a safety rating of "MODERATE" in our database. EU status: restricted. US status: restricted. 10 toxicological study endpoint(s) are available in our database.
Also known as: 3,3,5-Trimethylcyclohexylsalicylate (Homosalate), Benzoic acid, 2-hydroxy-, 3,3,5-trimethylcyclohexyl ester, Caswell No. 482B, Coppertone, EINECS 204-260-8 (+9 more)
INCI: HOMOSALATE
Homosalate (CAS 118-56-9) is a cosmetic active ingredient functioning as Oil-soluble UVB UV filter; peak absorption ~306 nm; used as SPF booster in. NOAEL 10 mg/kg bw/day (PDF-verified against ToxValDB ECHA IUCLID); EU Regulation 1223/2009 status: restricted, max 7.34%. Industrial safety data is also available in the chemical safety database. Same-CAS public records also appear in industrial chemical safety and pharmaceutical data.
Homosalate is classified GHS CMR hazard (H315, H319, H335, H361d, H410) in the chemicals database but is restricted in EU cosmetics at max 7.34%.
Source: Cosmetics: ingredients.eu status/eu max; Chemicals: ghs classifications.signal word/hazard statement code
For full compliance data across multiple jurisdictions, use the Substance Compliance tool.
Margin of Safety, dermal absorption, and sensitization profile summaries for Homosalate.
Calculate MoS for your specific formulation with the MoS Calculator.
10 study endpoints found for Homosalate. NOAEL (No Observed Adverse Effect Level) values are used to calculate the Margin of Safety per SCCS methodology.
| Endpoint | Value | Route | Species | Study Type | Source |
|---|---|---|---|---|---|
| NOAEL | =10 mg/kg bw/day | oral | - | repeated dose toxicity | SCCS Opinion |
| NOAEL | =10 mg/kg bw/d | oral | rat | dermal absorption | SCCS Opinion |
| NOAEL | =10 mg/kg bw/day | oral | - | repeated dose toxicity | SCCS Opinion |
| NOAEL | =10 mg/kg bw/day | oral | - | repeated dose toxicity | SCCS Opinion |
| NOAEL | =10 mg/kg bw/d | oral | rat | dermal absorption | SCCS Opinion |
| NOAEL | =10 mg/kg bw/day | oral | - | repeated dose toxicity | SCCS Opinion |
| NOAEL | =10 mg/kg bw/day | oral | - | repeated dose toxicity | SCCS Opinion |
| NOAEL | =10 mg/kg bw/d | oral | rat | dermal absorption | SCCS Opinion |
| NOAEL | =10 mg/kg bw/day | oral | - | repeated dose toxicity | SCCS Opinion |
| NOAEL | =10 mg/kg bw/day | oral | - | repeated dose toxicity | SCCS Opinion |
Pre-calculated NOAEL → SED → MoS audit trail for Homosalate across SCCS product categories, with measured dermal absorption where available.
NOAEL/LOAEL values cited in official SCCS opinions for Homosalate.
| NOAEL | LOAEL | Route | Species | Study | DA% (SCCS) | Opinion |
|---|---|---|---|---|---|---|
| 300 mg/kg/day | 750 mg/kg/day | Oral | Rat (Wistar RccHan) | Combined repeated dose + reproductive screening (OECD 422) (28 days) | 100 | SCCS/1622/20 (2021) |
| 10 mg/kg/day | 60 mg/kg/day | Oral | Rat (Wistar) | Combined repeated dose + reproductive screening (OECD 422) (28 days) | 100 | SCCS/1638/21 (2021) |
Skin absorption and penetration characteristics of Homosalate, relevant to systemic exposure and MoS calculations.
Source: SCCS Opinion
10 toxicity values from EPA ToxValDB (aggregated from CCTE, HPV, ToxRefDB, IRIS, and other regulatory dossiers).
| Endpoint | Value | Species | Route | Duration | Source |
|---|---|---|---|---|---|
| LEL | =750 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =750 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =750 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =750 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =300 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =300 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =300 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =750 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =750 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
| LOAEL | =300 mg/kg-day | Rat | oral | subchronic (developmental) | EPA TSCA 8e |
2 human repeat insult patch tests aggregated from dermatological literature.
| Test Type | N | Sensitized | Dose µg/cm² | NESIL µg/cm² | Potency |
|---|---|---|---|---|---|
| HRIPT | - | 0 | - | - | non-sensitizer |
| HMT | - | 0 | - | - | - |
Cross-referenced EDC classifications, mechanism data, and dose-response evidence from EDLists, SIN List, and cosmetic-specific detail sources.
Source list: II (former)
agonist (ERα); antagonist (AR)
| Endpoint | Target | Value | Direction |
|---|---|---|---|
| IC50_AR | AR | 5.87 µM | antagonist |
| Cell proliferation | ER | EC50/IC50: ~3 uM (EC50, weaker than 4-MBC); LOEC: 1 uM; NOEC: 0.3 uM mixed | agonist |
| Estrogen response element reporter activation | ERa | EC50/IC50: AC50 14.20 uM; LOEC: ~8.86 uM (ACC); NOEC: ~1 uM mixed | agonist |
| AR/PR-mediated transcription (antagonist) | AR; PR | EC50/IC50: IC50 ~3-10 uM (AR); IC50 ~1-3 uM (PR); LOEC: 1 uM; NOEC: 0.1 uM mixed | antagonist |
European Chemicals Agency REACH dossier and Substances of Very High Concern listing.
European Commission CosIng database Annex references per Regulation (EC) No 1223/2009.
Additional regulatory detail beyond the 7-jurisdiction summary: Saudi SFDA, Korea MFDS, ASEAN ACD, Japan/Korea, Brazil/India, and cross-jurisdictional restriction entries.
| Jurisdiction | Status | Max % | Product Type |
|---|---|---|---|
| JP | restricted | 10% | All cosmetics |
| CN | permitted_uv_filter | 10 | All cosmetics |
| IN | permitted_uv_filter | 10.0 | sunscreen and other cosmetic products |
| AU | restricted | - | sunscreens (therapeutic) |
| GCC | restricted | 7.34 | Sunscreen products |
| BR | permitted_uv_filter | 15 | Sunscreen products; EU max 10% |
| UK | restricted | - | - |
| ID | permitted_uv_filter | 10% (ASEAN-wide); Indonesia reducing per PerBPOM 25/2025 | - |
Cross-database dermal penetration: EPA Dryad physics-based, Roberts Mendeley permeation, and SCCS-aggregated measured values.
| Type | DA % | Method | Skin Model | SCCS Ref |
|---|---|---|---|---|
| measured_in_vitro | 5.3 | In vitro — flow-through diffusion cells | - | SCCS/1622/20; SCCS/1260/22 (2020) |
| measured_in_vitro | 11.0 | - | - | SCCS/1564/15 |
Preliminary editorial summary for Homosalate — not a computed safety verdict. See the sourced toxicological data above.
Public NOAEL study rows linked to Homosalate by CAS number or substance name.
Units vary across source rows: mg/kg bw/day, mg/kg bw/d, mg/kg/day
| Absorption % | Method | Vehicle |
|---|---|---|
| 5.3 | In vitro — flow-through diffusion cells | Standard sunscreen formulation (o/w) |
| 11.0 | - | - |
Same-CAS public records found in pharmaceutical data.
Same-CAS rows from the pharmaceutical spoke database.
Homosalate has a safety rating of "MODERATE" in our database. EU status: restricted. US status: restricted. 10 toxicological study endpoint(s) are available in our database.
Homosalate EU regulatory status: restricted. Maximum allowed concentration: 7.34%. This is based on EU Regulation 1223/2009 and its amendments.
Homosalate functions as: Oil-soluble UVB UV filter; peak absorption ~306 nm; used as SPF booster in combination formulations; UVB-only spectrum with no UVA coverage. It is classified as a Active Ingredient in our database. CAS number: 118-56-9.
The NOAEL (No Observed Adverse Effect Level) for Homosalate is =10 mg/kg bw/day based on a repeated dose toxicity study via oral route in rat. A total of 10 study endpoints are available. Source: SCCS Opinion.
Homosalate also appears in industrial chemical safety and pharmaceutical data. The cross-vertical cards on this page render same-CAS public rows from the matched databases.
Homosalate is classified GHS CMR hazard (H315, H319, H335, H361d, H410) in the chemicals database but is restricted in EU cosmetics at max 7.34%.
Check Homosalate compliance across multiple jurisdictions:
Scan any product label with Piro — our free ingredient scanner. Point your camera at the ingredients list and get instant safety scores for every ingredient.
Try Piro Free →Paste any INCI list into the Decoder for instant safety analysis, or calculate the Margin of Safety for Homosalate in your formulation.